+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues



Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues



Journal der Deutschen Dermatologischen Gesellschaft 10(3): 167-172



Atopic dermatitis is a common chronic skin disorder whose management is complex. Topical corticosteroids have been the mainstay of atopic dermatitis treatment for more than 50 years but have multiple side effects. Topical calcineurin inhibitors including tacrolimus and pimecrolimus are safe and efficacious in atopic dermatitis. In 2005 the FDA issued "black box" warnings for pimecrolimus cream and tacrolimus ointment because of potential safety risks, including skin cancers and lymphomas. However, these concerns are not supported by current data. Topical calcineurin inhibitors are particularly indicated for treating patients with atopic dermatitis in whom topical corticosteroid therapy cannot be employed or may cause irreversible side effects. They can be used advantageously in problem zones. A novel regimen of proactive treatment has been shown to prevent, delay and reduce exacerbations of atopic dermatitis. Therapy with topical calcineurin inhibitors should be managed by an experienced specialist and each patient should receive proper education on how to use them and what possible unwanted effects may be expected.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056605066

Download citation: RISBibTeXText

PMID: 21974750

DOI: 10.1111/j.1610-0387.2011.07791.x


Related references

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medgenmed 8(4): 8, 2007

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 6(2): 65-77, 2005

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatovenerologica Alpina, Pannonica, et Adriatica 16(2): 58, 60-62, 2007

Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Current Allergy and Asthma Reports 6(4): 270-274, 2006

Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatric Drugs 9(5): 289-299, 2007

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Bmc Pediatrics 16: 75, 2017

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 26(3): 122-132, 2016

Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology 5(4): 267-279, 2004

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults. Allergy, Asthma, and Clinical Immunology 9(1): 24-24, 2013

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54(5): 424-431, 2003

Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. American Journal of Clinical Dermatology 7(4): 213-222, 2006